TrialPloS one2023

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.

Jonas Sundén-Cullberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.